Bortezomib, rituximab,and dexamethason (BORID) induces high response ratesand durable complete remissions in patients with relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Drach, J. [1 ]
Kaufmann, H. [1 ]
Pichelmayer, O. [1 ]
Sagaster, V. [1 ]
Seidl, S. [1 ]
Zielinski, C. [1 ]
Chott, A. [1 ]
Raderer, M. [1 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1188
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [1] Bortezomib, rituximab, and dexamethason (BORID) is an active salvage regimen for patients with relapsed/refractory mantle cell lymphoma
    Drach, J.
    Kaufmann, H.
    Pichelmayer, O.
    Sagaster, V.
    Holzer, S.
    Zielinski, C.
    Raderer, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 214 - 214
  • [2] Promising activity of bortezomib, rituximab, and dexamethason (BORID) in patients with relapsed mantle cell lymphoma
    Drach, J
    Seidl, S
    Pichelmayer, O
    Kaufmann, H
    Zielinski, C
    Raderer, M
    BLOOD, 2005, 106 (11) : 280B - 280B
  • [3] Bortezomib, rituximab, and dexamethason (BORID) as salvage treatment in relapsed/refractory mantle cell lymphoma: Sustained disease control in patients achieving a complete remission
    Drach, Johannes
    Kaufmann, Hannes
    Pichelmayer, Oskar
    Sagaster, Verena
    Holzer, Sonja
    Odelga, Viktoria
    Zielinski, Christoph
    Raderer, Markus
    BLOOD, 2007, 110 (11) : 760A - 760A
  • [4] Marked activity of, bortezomib, rituximab, and dexamethason in relapsed and refractory mantle cell lymphoma.
    Drach, Johannes
    Kaufmann, Hannes
    Pichelmayer, Oskar
    Sagaster, Verena
    Seidl, Sonja
    Chott, Andreas
    Zielinski, Christoph
    Raderer, Markus
    BLOOD, 2006, 108 (11) : 779A - 779A
  • [5] Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma.
    Drach, J
    Kaufmann, H
    Woehrer, S
    Chott, A
    Zielinski, CC
    Raderer, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 578S - 578S
  • [6] Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab
    Cencini, Emanuele
    Guerrini, Susanna
    Mazzei, Maria Antonietta
    Chiappella, Annalisa
    Fabbri, Alberto
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (05) : 435 - 440
  • [7] Fludarabine, Bortezomib, Myocet® and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma
    Orciuolo, Enrico
    Buda, Gabriele
    Pelosini, Matteo
    Petrini, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (05) : 810 - 812
  • [8] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [9] Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
    Phillips, Tycel
    Dickinson, Michael
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Lundberg, Linda
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David
    Byrne, Ben
    Qayum, Naseer
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S462 - S462
  • [10] Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed/ Refractory Mantle Cell Lymphoma
    Phillips, Tycel
    Dickinson, Michael
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Nancy, Bartlett L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Lundberg, Linda
    Relf, James
    de L'Etang, Filezac Audrey
    Carlile, David
    Byrne, Ben
    Qayum, Naseer
    Carlo-Stella, Carmelo
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S52 - S53
12345